emeis Société anonyme

ENXTPA:EMEIS Stock Report

Market Cap: €942.5m

emeis Société anonyme Valuation

Is EMEIS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EMEIS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: EMEIS (€5.86) is trading below our estimate of fair value (€85.24)

Significantly Below Fair Value: EMEIS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EMEIS?

Key metric: As EMEIS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for EMEIS. This is calculated by dividing EMEIS's market cap by their current earnings.
What is EMEIS's PE Ratio?
PE Ratio0.6x
Earnings€1.47b
Market Cap€942.52m

Price to Earnings Ratio vs Peers

How does EMEIS's PE Ratio compare to its peers?

The above table shows the PE ratio for EMEIS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average13.9x
LNA LNA Santé
10.9x7.4%€259.7m
EQS Equasens Société anonyme
15.2x11.4%€640.3m
GBT Guerbet
10.4x18.3%€341.1m
BLC Bastide Le Confort Médical
19.3x34.1%€142.4m
EMEIS emeis Société anonyme
0.6x-108.0%€942.5m

Price-To-Earnings vs Peers: EMEIS is good value based on its Price-To-Earnings Ratio (0.6x) compared to the peer average (13.9x).

Price to Earnings Ratio vs Industry

How does EMEIS's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.18.2x25.0%
EMEIS emeis Société anonyme
 0.6x-108.0%US$992.24m
EMEIS 0.6xIndustry Avg. 18.2xNo. of Companies9PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
Industry Avg.18.2x25.0%
EMEIS emeis Société anonyme
 0.6x-108.0%US$992.24m
No more companies

Price-To-Earnings vs Industry: EMEIS is good value based on its Price-To-Earnings Ratio (0.6x) compared to the European Healthcare industry average (18.2x).

Price to Earnings Ratio vs Fair Ratio

What is EMEIS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EMEIS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio0.6x
Fair PE Ratio2.9x

Price-To-Earnings vs Fair Ratio: EMEIS is good value based on its Price-To-Earnings Ratio (0.6x) compared to the estimated Fair Price-To-Earnings Ratio (2.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst EMEIS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€5.86
€10.53
+79.8%
28.6%€14.00€7.20n/a4
Nov ’25€6.31
€11.63
+84.5%
23.0%€14.00€7.90n/a3
Oct ’25€5.47
€11,633.33
+212,419.8%
23.0%€14,000.00€7,900.00n/a3
Sep ’25€8.98
€11,633.33
+129,418.3%
23.0%€14,000.00€7,900.00n/a3
Aug ’25€10.29
€11,633.33
+112,976.7%
23.0%€14,000.00€7,900.00n/a3
Jul ’25€12.31
€11,725.00
+95,132.3%
24.7%€15,000.00€7,900.00n/a4
Jun ’25€12.94
€11,725.00
+90,510.5%
24.7%€15,000.00€7,900.00n/a4
May ’25€12.80
€10,975.00
+85,642.2%
20.7%€14,000.00€7,900.00n/a4
Apr ’25€10.14
€6,230.00
+61,352.0%
95.5%€14,000.00€20.00n/a4
Mar ’25€12.60
€3,640.00
+28,788.9%
123.9%€10,000.00€20.00n/a3
Feb ’25€13.50
€2,737.50
+20,177.8%
153.7%€10,000.00€20.00n/a4
Jan ’25€16.90
€2,737.50
+16,098.2%
153.7%€10,000.00€20.00n/a4
Dec ’24€16.40
€2,737.50
+16,592.1%
153.7%€10,000.00€20.00n/a4
Nov ’24€894.99
€3,910.00
+336.9%
117.1%€10,000.00€20.00€6.315
Oct ’24€1,424.50
€3,909.99
+174.5%
117.1%€10,000.00€20.00€5.475
Sep ’24€1,672.50
€3,909.99
+133.8%
117.1%€10,000.00€20.00€8.985
Aug ’24€1,740.49
€3,939.99
+126.4%
115.6%€10,000.00€30.02€10.295
Jul ’24€1,889.49
€4,005.97
+112.0%
112.3%€10,000.00€170.01€12.315
Jun ’24€1,849.99
€4,917.48
+165.8%
93.5%€10,000.00€170.01€12.944
May ’24€2,676.00
€5,561.99
+107.8%
76.7%€10,000.00€289.94€12.805
Apr ’24€1,966.99
€5,601.65
+184.8%
69.5%€10,000.00€289.94€10.146
Mar ’24€2,476.00
€10,944.27
+342.0%
124.0%€43,000.00€289.94€12.607
Feb ’24€5,539.99
€13,688.58
+147.1%
91.1%€43,000.00€4,000.00€13.507
Jan ’24€6,171.99
€17,165.00
+178.1%
86.5%€43,000.00€4,000.00€16.908
Dec ’23€6,694.00
€17,415.00
+160.2%
84.1%€43,000.00€5,799.97€16.408
Nov ’23€9,195.99
€25,928.56
+182.0%
56.1%€43,000.00€7,000.00€894.997

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Laboratoires Euromedis Société anonyme

€13.6m

Through its subsidiaries, designs, manufactures, and distributes medical equipment under the Euromedis brand name for healthcare professionals, local communities, and individuals in France and internationally.

ALEMG

€4.77

7D

-8.6%

1Y

-1.4%

bioMérieux

€11.6b

Develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

BIM

€98.35

7D

-3.9%

1Y

2.6%

Ramsay Générale de Santé

€1.3b

Operates healthcare facilities in France, Sweden, Norway, Denmark, and Italy.

GDS

€12.05

7D

0%

1Y

-42.1%